# Inside Germany’s biotech capital infrastructure and innovation engine

Page: https://stenobird.com/podcast/biospace-6696251/inside-germany-s-biotech-capital-infrastructure-and-innovation-engine
Text version: https://stenobird.com/podcast/biospace-6696251/inside-germany-s-biotech-capital-infrastructure-and-innovation-engine.md
Podcast: [BioSpace](https://stenobird.com/podcast/biospace-6696251)
Published: 2026-05-21T07:00:00+00:00
Episode link: https://api.riverside.com/hosting-analytics/media/68216bacc58a087b74d0216d50f11d8f16f70d0a53ec603f8c51603fc26f8365/eyJlcGlzb2RlSWQiOiI0MjkxYzAyZi03OGVmLTRlMDEtYjVkZi1jMWQxYTFlMDM0NDAiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmEwZGMzOTBmYmM4ZDFlNDI2MmY1OTIxL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi01LTIwX18xNi0yMi04Lm1wMyJ9.mp3
Audio file: https://api.riverside.com/hosting-analytics/media/68216bacc58a087b74d0216d50f11d8f16f70d0a53ec603f8c51603fc26f8365/eyJlcGlzb2RlSWQiOiI0MjkxYzAyZi03OGVmLTRlMDEtYjVkZi1jMWQxYTFlMDM0NDAiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmEwZGMzOTBmYmM4ZDFlNDI2MmY1OTIxL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi01LTIwX18xNi0yMi04Lm1wMyJ9.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/inside-germany-s-biotech-capital-infrastructure-and-innovation-engine
Duration seconds: 1397

## Resource

In this episode of Denatured, as part of our series of the European life science investment ecosystem, you'll be hearing from Regina Hodits, managing director at Angelini Ventures and Sofia Ioannidou, VC partner at Andera Life Sciences. They examine Germany’s biotech and life sciences landscape, focusing on the scientific, infrastructure and policy shifts required to enable European companies to scale globally while remaining anchored in Europe. Host ⁠Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Regina Hodits , Managing Director, Angelini Ventures Sofia Ioannidou , VC Partner, Andera Life Sciences Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/inside-germany-s-biotech-capital-infrastructure-and-innovation-engine/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/biospace-6696251/inside-germany-s-biotech-capital-infrastructure-and-innovation-engine.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.